InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,509.01
(
0.62%
)
US TECH 100
19,478.00
(
1.04%
)
Dow Jones
39,331.85
(
0.41%
)
Brent Oil
86.35
(
-0.21%
)
Bitcoin
61,942.98
(
-1.44%
)
Post# of 252464
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119970
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 54970

Sunday, 11/18/2007 9:02:05 PM

Sunday, November 18, 2007 9:02:05 PM

Post# of 252464
>Why doesn't MNTA immediately expand their current M-118 trials with the assets they currently have?<

MNTA has talked about running a phase-2 trial in ACS. In fact, ACS, rather than stable angina, was originally slated to be the lead M118 indication. However, now that revenues from generic Lovenox have been pushed out to some degree, the second phase-2 trial for M118 may be on the back burner.

>Or, would the cash drain be excessive given the entire pipeline cost?<

The company’s guidance is for $132M in cash at year-end 2007. This sounds like a lot, but MNTA is doing a lot of R&D and not all of it is funded by NVS.

The kind of phase-2 program I envision for M118 is on a scale comparable to what VRTX and JNJ are doing with Telaprevir. To do that, I think MNTA needs a partner.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up